Prescription patterns and efficacy of drugs for patients with dementia: Physicians' perspective in Italy

Aging Clinical and Experimental Research

Volumn 19, Issue 5, 2007, Pages 349-355

  Frisoni, Giovanni B ^a   Canu, Elisa ^a   Geroldi, Cristina ^a   Brignoli, Barbara ^a   Anglani, Livio ^a   Galluzzi, Samantha ^a   Zacchi, Valeria ^a   Zanetti, Orazio ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Cognitive symptoms; Dementia; Drugs; Efficacy; Non cognitive symptoms

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; NEUROLEPTIC AGENT; NOOTROPIC AGENT; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DRUG EFFICACY; FREQUENCY ANALYSIS; FRONTOTEMPORAL DEMENTIA; HEALTH SURVEY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MULTIINFARCT DEMENTIA; OFF LABEL DRUG USE; PHYSICIAN ATTITUDE; PRESCRIPTION; PREVALENCE; RATING SCALE; STRUCTURED QUESTIONNAIRE;

PUFFINUS AURICULARIS;

EID: 37348999220     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324714     Document Type: Article

References (59)

1. Evans JG, Wilcock G, Birks J. Evidence-based pharmacotherapy of Alzheimer's disease. Int J Neuropsychopharmacol 2004; 7: 351-69.
2. Mayeux R, Sano M. Treatment of Alzheimer's Disease. N Engl J Med 1999; 341: 1670-9.
3. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-15.
4. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005; 331: 321-7.
5. Kmietowicz Z. NICE proposes to withdraw Alzheimer's drugs from NHS. BMJ 2005; 330: 495.
6. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardio-vascular health study. JAMA 2002; 288: 1475-83.
7. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329: 75.
8. Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998; 155: 1512-20.
9. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946-55.
10. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26: 494-504.
11. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIAD. Arch Gen Psychiatry 2003; 60: 737-46.
12. Finkel SI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther 2004; 26: 980-90.
13. Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1997; 9: 591-3.
14. Teri L, Logsdon RG, Peskind E, et al. Alzheimer's Disease Cooperative Study. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55:1271-8. Erratum in: Neurology 2001; 56: 426.
15. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in ale treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214-9.
16. Gauathier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8.
17. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-30.
18. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-45.
19. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999; 56: 1388-93.
20. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-6.
21. Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002; 13: 183-92.
22. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283-90.
23. Black S, Roman GC, Geldmacher DS, et al. Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-30.
24. Wilkinson D, Doody R, Helme R, et al. Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61: 479-86.
25. Ministerodellasalute-Medicinali e vigilanza-Informazione sui farmaci [Ministero della salute web atel. November 2, 2005. Available at: www.alzheimer-cronos.it; http://www.ministerosalute.it/imgs/ C_17_notaInf_1_listaFile_itemName_0_file.pdf; http://www.ministerosalute.it/imgs/C_17_notaInf_1_listaFile_itemName_ 1_file.pdf.; Accessed May 5, 2006.
26. Frisoni GB: Centro Alzheimer [Centro Alzheimer web site]. October 29, 2005. Available at: http://www.centroalzheimer.it/ricuva.htm; Accessed July 24, 2006.
27. Frisoni GB, Canu E, Geroldi C, Zanetti O, Zacchi V. Drug prescription in mild cognitive impairment: the physicians' perspective in Italy. Int J Geriatr Psychiatry 2006; 21: 1071-7.
28. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8.
29. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-76.
30. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001; 49: 1590-9.
31. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-8.
32. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293-303.
33. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44.
34. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20. Erratum in: Neurology 2001; 57: 2153.
35. Suh GH, Yeon Jung H, Uk Lee C, et al. Korean Galantamine Study Group. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clin Ther 2004; 26: 1608-18.
36. Seltzer B, Zolnouni P, Nunez M, et al. Donepezil "402" Study Group. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004; 61: 1852-6.
37. Karaman Y, Erdogan F, Koseoglu E, Turan T, Ersoy AO. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 19: 51-6.
38. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 2664; 21: 931-7.
39. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002; (4):CD003120.
40. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in ale elderly. Cochrane Database Syst Rev 2004; (2): CD000269.
41. Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev 2003; (2): CD003158.
42. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev2003; (1): CD003119.
43. Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001; (4): CD003159.
44. Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2001; (2): CD001011.
45. Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia. Cochrane Database Syst Rev 2001; (2): CD000359.
46. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004; 351: 1885-90.
47. Tenery RM. Interactions between physicians and the health care technology industry. JAMA 2000; 283: 391-3.
48. Editorial. Drug-company influence on medical education in USA. Lancet 2000; 356: 781.
49. Mulrow CD, Cook DJ, Davidoff F. Systematic reviews: critical links in the great chain of evidence. Ann Intern Med 1997; 126: 389-91.
50. Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 2004; 65 (Suppl 11): 11-5.
51. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293: 596-608.
52. Tamblyn R, Abrahamowicz M, du Berger R, McLeod P, Bartlett G. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005; 53: 233-41.
53. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med 2004; 164: 1567-72.
54. Hemmelgam B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997; 278: 27-31.
55. Foy A, O'Connell D, Henry D, Kelly J, Cocking S, Halliday J. Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients. J Gerontol A Biol Sci Med Sci 1995; 50: M99-106.
56. Shorr RI, Robin DW. Rational use of benzodiazepines in the elderly. Drugs Aging 1994; 4: 9-20.
57. Galinsky DE. Caution on use of benzodiazepines in the elderly. N Engl J Med 1979; 300: 1054-5.
58. Frisoni GB. Diagnosi e Terapia della malattia di Alzheimer: Un percorso per le Unità di Valutazione Alzheimer. Ed. Fatebenefratelli, 2004.
59. Bellelli G, Lucchi E, Minicuci N, et al. Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the "real world" (CRONOS project): a 36-week follow-up study. Aging Clin Exp Res 2005; 17: 54-61.